Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 68472 entries
Sorted by: Best Match Show Resources per page
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.

Trials

Akova M, Unal S.
PMID: 33849629
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.

OBJECTIVES: The primary objective is to evaluate the efficacy of an inactivated and aluminium hydroxide adsorbed SARS-CoV-2 vaccine (Sinovac, China) in voluntary participants after 14 days of the second dose against RT-PCR confirmed symptomatic COVID-19 cases. The secondary objectives...

Cite
Akova M, Unal S. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Trials. 2021;22(1):276doi: 10.1186/s13063-021-05180-1.
Akova, M., & Unal, S. (2021). A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Trials, 22(1), 276. https://doi.org/10.1186/s13063-021-05180-1
Akova, Murat, and Unal, Serhat. "A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial." Trials vol. 22,1 (2021): 276. doi: https://doi.org/10.1186/s13063-021-05180-1
Akova M, Unal S. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1. PMID: 33849629; PMCID: PMC8042350.
Copy Download .nbib Format: NLM
Electrical injuries. Biological values measurements as a prediction factor of local evolution in electrocutions lesions.

Journal of medicine and life

Teodoreanu R, Popescu SA, Lascar I.
PMID: 25408731
J Med Life. 2014 Jun 15;7(2):226-36. Epub 2014 Jun 25.

RATIONALE: Taking into account the incidence and the severity of electrocutions, we consider it extremely necessary to find effective, appropriate and particularized therapeutic solutions aimed at improving the survival, decreasing the mortality, ensuring a superior functional and aesthetic effect...

Cite
Teodoreanu R, Popescu SA, Lascar I. Electrical injuries. Biological values measurements as a prediction factor of local evolution in electrocutions lesions. J Med Life. 2014;7(2):226-36
Teodoreanu, R., Popescu, S. A., & Lascar, I. (2014). Electrical injuries. Biological values measurements as a prediction factor of local evolution in electrocutions lesions. Journal of medicine and life, 7(2), 226-36.
Teodoreanu, R, et al. "Electrical injuries. Biological values measurements as a prediction factor of local evolution in electrocutions lesions." Journal of medicine and life vol. 7,2 (2014): 226-36.
Teodoreanu R, Popescu SA, Lascar I. Electrical injuries. Biological values measurements as a prediction factor of local evolution in electrocutions lesions. J Med Life. 2014 Jun 15;7(2):226-36. Epub 2014 Jun 25. PMID: 25408731; PMCID: PMC4197509.
Copy Download .nbib Format: NLM
Molecular biological assessment methods and understanding the course of the HIV infection.

APMIS. Supplementum

Katzenstein TL.
PMID: 14626050
APMIS Suppl. 2003;(114):1-37.

Only some twenty years has passed since the first discovery of severe immunodeficiency among previously healthy homosexual men through the discovery of the causing virus and till the status today where the knowledge on the HIV virus and the...

Cite
Katzenstein TL. Molecular biological assessment methods and understanding the course of the HIV infection. APMIS Suppl. 2003;(114):1-37
Katzenstein, T. L. (2003). Molecular biological assessment methods and understanding the course of the HIV infection. APMIS. Supplementum, (114), 1-37.
Katzenstein, Terese L. "Molecular biological assessment methods and understanding the course of the HIV infection." APMIS. Supplementum vol. ,114 (2003): 1-37.
Katzenstein TL. Molecular biological assessment methods and understanding the course of the HIV infection. APMIS Suppl. 2003;(114):1-37. PMID: 14626050.
Copy Download .nbib Format: NLM
Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.

The Cochrane database of systematic reviews

Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.
PMID: 28440858
Cochrane Database Syst Rev. 2017 Apr 25;4:CD012200. doi: 10.1002/14651858.CD012200.pub2.

BACKGROUND: The treatment of multiple sclerosis has changed over the last 20 years. The advent of disease-modifying drugs in the mid-1990s heralded a period of rapid progress in the understanding and management of multiple sclerosis. With the support of...

Cite
Filippini G, Del Giovane C, Clerico M, et al. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Cochrane Database Syst Rev. 2017;4:CD012200doi: 10.1002/14651858.CD012200.pub2.
Filippini, G., Del Giovane, C., Clerico, M., Beiki, O., Mattoscio, M., Piazza, F., Fredrikson, S., Tramacere, I., Scalfari, A., & Salanti, G. (2017). Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. The Cochrane database of systematic reviews, 4CD012200. https://doi.org/10.1002/14651858.CD012200.pub2
Filippini, Graziella, et al. "Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis." The Cochrane database of systematic reviews vol. 4 (2017): CD012200. doi: https://doi.org/10.1002/14651858.CD012200.pub2
Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Cochrane Database Syst Rev. 2017 Apr 25;4:CD012200. doi: 10.1002/14651858.CD012200.pub2. PMID: 28440858; PMCID: PMC6478290.
Copy Download .nbib Format: NLM
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.

The Cochrane database of systematic reviews

Tramacere I, Del Giovane C, Salanti G, D'Amico R, Filippini G.
PMID: 26384035
Cochrane Database Syst Rev. 2015 Sep 18;(9):CD011381. doi: 10.1002/14651858.CD011381.pub2.

BACKGROUND: Different therapeutic strategies are available for the treatment of people with relapsing-remitting multiple sclerosis (RRMS), including immunomodulators, immunosuppressants and biologics. Although there is consensus that these therapies reduce the frequency of relapses, their relative benefit in delaying new...

Cite
Tramacere I, Del Giovane C, Salanti G, et al. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2015;(9):CD011381doi: 10.1002/14651858.CD011381.pub2.
Tramacere, I., Del Giovane, C., Salanti, G., D'Amico, R., & Filippini, G. (2015). Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. The Cochrane database of systematic reviews, (9), CD011381. https://doi.org/10.1002/14651858.CD011381.pub2
Tramacere, Irene, et al. "Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis." The Cochrane database of systematic reviews vol. ,9 (2015): CD011381. doi: https://doi.org/10.1002/14651858.CD011381.pub2
Tramacere I, Del Giovane C, Salanti G, D'Amico R, Filippini G. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2015 Sep 18;(9):CD011381. doi: 10.1002/14651858.CD011381.pub2. PMID: 26384035.
Copy Download .nbib Format: NLM
Low-density lipoprotein apheresis: an evidence-based analysis.

Ontario health technology assessment series

[No authors listed]
PMID: 23074505
Ont Health Technol Assess Ser. 2007;7(5):1-101. Epub 2006 Nov 01.

OBJECTIVE: To assess the effectiveness and safety of low-density lipoprotein (LDL) apheresis performed with the heparin-induced extracorporeal LDL precipitation (HELP) system for the treatment of patients with refractory homozygous (HMZ) and heterozygous (HTZ) familial hypercholesterolemia (FH). BACKGROUND ON FAMILIAL...

Cite
Low-density lipoprotein apheresis: an evidence-based analysis. Ont Health Technol Assess Ser. 2006;7(5):1-101
(2007). Low-density lipoprotein apheresis: an evidence-based analysis. Ontario health technology assessment series, 7(5), 1-101.
"Low-density lipoprotein apheresis: an evidence-based analysis." Ontario health technology assessment series vol. 7,5 (2007): 1-101.
Low-density lipoprotein apheresis: an evidence-based analysis. Ont Health Technol Assess Ser. 2007;7(5):1-101. Epub 2006 Nov 01. PMID: 23074505; PMCID: PMC3377562.
Copy Download .nbib Format: NLM
Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants.

The Cochrane database of systematic reviews

Ohlsson A, Lacy JB.
PMID: 14973955
Cochrane Database Syst Rev. 2004;(1):CD000361. doi: 10.1002/14651858.CD000361.pub2.

BACKGROUND: Nosocomial infections continue to be a significant cause of morbidity and mortality among preterm and/or low birth weight infants. Maternal transport of immunoglobulins to the fetus mainly occurs after 32 weeks gestation and endogenous synthesis does not begin...

Cite
Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Cochrane Database Syst Rev. 2004;(1):CD000361doi: 10.1002/14651858.CD000361.pub2.
Ohlsson, A., & Lacy, J. B. (2004). Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. The Cochrane database of systematic reviews, (1), CD000361. https://doi.org/10.1002/14651858.CD000361.pub2
Ohlsson, A, and Lacy, J B. "Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants." The Cochrane database of systematic reviews vol. ,1 (2004): CD000361. doi: https://doi.org/10.1002/14651858.CD000361.pub2
Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Cochrane Database Syst Rev. 2004;(1):CD000361. doi: 10.1002/14651858.CD000361.pub2. PMID: 14973955.
Copy Download .nbib Format: NLM
Macroamylasemia attributable to gluten-related amylase autoantibodies: a case report.

Pediatrics

Barera G, Bazzigaluppi E, Viscardi M, Renzetti F, Bianchi C, Chiumello G, Bosi E.
PMID: 11389291
Pediatrics. 2001 Jun;107(6):E93. doi: 10.1542/peds.107.6.e93.

BACKGROUND: Macroamylasemia (MA) is a benign condition caused by circulating macroamylase complexes of pancreatic or salivary amylase bound to plasma proteins, which cannot be cleared by the renal glomeruli. In most cases, the macromolecular amylase represents a complex of...

Cite
Barera G, Bazzigaluppi E, Viscardi M, et al. Macroamylasemia attributable to gluten-related amylase autoantibodies: a case report. Pediatrics. 2001;107(6):E93doi: 10.1542/peds.107.6.e93.
Barera, G., Bazzigaluppi, E., Viscardi, M., Renzetti, F., Bianchi, C., Chiumello, G., & Bosi, E. (2001). Macroamylasemia attributable to gluten-related amylase autoantibodies: a case report. Pediatrics, 107(6), E93. https://doi.org/10.1542/peds.107.6.e93
Barera, G, et al. "Macroamylasemia attributable to gluten-related amylase autoantibodies: a case report." Pediatrics vol. 107,6 (2001): E93. doi: https://doi.org/10.1542/peds.107.6.e93
Barera G, Bazzigaluppi E, Viscardi M, Renzetti F, Bianchi C, Chiumello G, Bosi E. Macroamylasemia attributable to gluten-related amylase autoantibodies: a case report. Pediatrics. 2001 Jun;107(6):E93. doi: 10.1542/peds.107.6.e93. PMID: 11389291.
Copy Download .nbib Format: NLM
Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants.

The Cochrane database of systematic reviews

Ohlsson A, Lacy JB.
PMID: 11405962
Cochrane Database Syst Rev. 2001;(2):CD000361. doi: 10.1002/14651858.CD000361.

BACKGROUND: Nosocomial infections continue to be a significant cause of morbidity and mortality among preterm and/or low birth weight infants. Maternal transport of immunoglobulins to the fetus mainly occurs after 32 weeks gestation and endogenous synthesis does not begin...

Cite
Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Cochrane Database Syst Rev. 2001;(2):CD000361doi: 10.1002/14651858.CD000361.
Ohlsson, A., & Lacy, J. B. (2001). Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. The Cochrane database of systematic reviews, (2), CD000361. https://doi.org/10.1002/14651858.CD000361
Ohlsson, A, and Lacy, J B. "Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants." The Cochrane database of systematic reviews vol. ,2 (2001): CD000361. doi: https://doi.org/10.1002/14651858.CD000361
Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Cochrane Database Syst Rev. 2001;(2):CD000361. doi: 10.1002/14651858.CD000361. PMID: 11405962.
Copy Download .nbib Format: NLM
Intravenous immunoglobulin for suspected or proven infection in neonates.

The Cochrane database of systematic reviews

Ohlsson A, Lacy JB.
PMID: 25815707
Cochrane Database Syst Rev. 2015 Mar 27;(3):CD001239. doi: 10.1002/14651858.CD001239.pub5.

BACKGROUND: Neonates are at higher risk of infection due to immuno-incompetence. Maternal transport of immunoglobulins to the fetus mainly occurs after 32 weeks' gestation, and endogenous synthesis begins several months after birth. Administration of intravenous immunoglobulin (IVIG) provides immunoglobulin...

Cite
Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database Syst Rev. 2015;(3):CD001239doi: 10.1002/14651858.CD001239.pub5.
Ohlsson, A., & Lacy, J. B. (2015). Intravenous immunoglobulin for suspected or proven infection in neonates. The Cochrane database of systematic reviews, (3), CD001239. https://doi.org/10.1002/14651858.CD001239.pub5
Ohlsson, Arne, and Lacy, Janet B. "Intravenous immunoglobulin for suspected or proven infection in neonates." The Cochrane database of systematic reviews vol. ,3 (2015): CD001239. doi: https://doi.org/10.1002/14651858.CD001239.pub5
Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database Syst Rev. 2015 Mar 27;(3):CD001239. doi: 10.1002/14651858.CD001239.pub5. PMID: 25815707.
Copy Download .nbib Format: NLM
Intravenous immunoglobulin for suspected or proven infection in neonates.

The Cochrane database of systematic reviews

Ohlsson A, Lacy JB.
PMID: 23821359
Cochrane Database Syst Rev. 2013 Jul 02;(7):CD001239. doi: 10.1002/14651858.CD001239.pub4.

BACKGROUND: Neonates are at higher risk of infection due to immuno-incompetence. Maternal transport of immunoglobulins to the fetus mainly occurs after 32 weeks' gestation, and endogenous synthesis begins several months after birth. Administration of intravenous immunoglobulin (IVIG) provides immunoglobulin...

Cite
Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database Syst Rev. 2013;(7):CD001239doi: 10.1002/14651858.CD001239.pub4.
Ohlsson, A., & Lacy, J. B. (2013). Intravenous immunoglobulin for suspected or proven infection in neonates. The Cochrane database of systematic reviews, (7), CD001239. https://doi.org/10.1002/14651858.CD001239.pub4
Ohlsson, Arne, and Lacy, Janet B. "Intravenous immunoglobulin for suspected or proven infection in neonates." The Cochrane database of systematic reviews vol. ,7 (2013): CD001239. doi: https://doi.org/10.1002/14651858.CD001239.pub4
Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database Syst Rev. 2013 Jul 02;(7):CD001239. doi: 10.1002/14651858.CD001239.pub4. PMID: 23821359.
Copy Download .nbib Format: NLM
Intravenous immunoglobulin for suspected or subsequently proven infection in neonates.

The Cochrane database of systematic reviews

Ohlsson A, Lacy JB.
PMID: 14973965
Cochrane Database Syst Rev. 2004;(1):CD001239. doi: 10.1002/14651858.CD001239.pub2.

BACKGROUND: Congenital and nosocomial infections are important causes of neonatal morbidity and mortality. Maternal transport of immunoglobulins to the fetus mainly occurs after 32 weeks gestation and endogenous synthesis does not begin until several months after birth. Administration of...

Cite
Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev. 2004;(1):CD001239doi: 10.1002/14651858.CD001239.pub2.
Ohlsson, A., & Lacy, J. B. (2004). Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. The Cochrane database of systematic reviews, (1), CD001239. https://doi.org/10.1002/14651858.CD001239.pub2
Ohlsson, A, and Lacy, J B. "Intravenous immunoglobulin for suspected or subsequently proven infection in neonates." The Cochrane database of systematic reviews vol. ,1 (2004): CD001239. doi: https://doi.org/10.1002/14651858.CD001239.pub2
Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev. 2004;(1):CD001239. doi: 10.1002/14651858.CD001239.pub2. PMID: 14973965.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 68472 entries